Neoadjuvant Chemotherapy by Liposomal Doxorubicin Boosts Immune Protection of Tumor Membrane Antigens-Based Nanovaccine

Using Liposomal Doxorubicin Neoadjuvant Chemotherapy to Enhance Immune Protection of Tumor Membrane Antigen-Based Nanovaccine Background and Significance Surgical resection remains the primary treatment for solid tumors, but postoperative tumor recurrence and metastasis continue to be major challenges. A promising emerging strategy in personalized ...

Mechanism of Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma

Research Report on Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma with Paricalcitol and Hydroxychloroquine Background Pancreatic Ductal Adenocarcinoma (PDAC) has an extremely low survival rate, with a 5-year survival rate of less than 15%. The primary reasons are early tumor metastasis and high resistance to chemotherapy and ra...

Coupling of Response Biomarkers Between Tumor and Peripheral Blood in Chemoimmunotherapy

Background Introduction This study focuses on malignant pleural mesothelioma (MPM), a rare and highly lethal cancer strongly associated with asbestos exposure. Most patients are diagnosed at advanced stages, with a survival time of only 12 to 15 months, and traditional treatments revolve around platinum-based chemotherapy. However, treatment paradi...

Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer

Research on a New Platform for Tumor-Specific Drug Delivery Targeting the Warburg Effect Cancer remains a global health challenge. Traditional cancer treatments, such as chemotherapy and radiotherapy, often come with significant side effects due to their inability to distinguish between tumor tissues and healthy tissues, leading to damage in the la...

3D Bioprinting of Tumor Models and Potential Applications

3D Bioprinting of Tumor Models and Their Potential Applications: A Review Academic Background Cancer is one of the leading causes of human mortality worldwide. Its uncontrolled abnormal proliferation, rapid growth, metastasis, and high heterogeneity result in extremely low clinical translation rates for traditional two-dimensional (2D) cell culture...

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis

Transcriptomic Concordance Between Borderline Ovarian Tumors and Endometrioid Carcinoma: A Research Study Background Introduction Borderline ovarian tumors (BOTs) are ovarian neoplasms that lie between benign and malignant tumors, typically occurring in young women. Although BOTs are clinically non-invasive, they can occasionally progress to malign...

Exploring Cervical Adenocarcinoma: Epidemiological Insights, Diagnostic and Therapeutic Challenges, and Pathogenetic Mechanisms

Exploring Cervical Adenocarcinoma: Epidemiology, Diagnostic and Therapeutic Challenges, and Pathogenetic Mechanisms Academic Background Cervical cancer poses a significant threat to women’s health globally, particularly in developing countries. The main histological types of cervical cancer include squamous cell carcinoma (SCC) and cervical adenoca...

Platelet-Activating Factor: A Potential Therapeutic Target to Improve Cancer Immunotherapy

The Potential Role of Platelet-Activating Factor in Cancer Immunotherapy Background Cancer immunotherapy has been a significant breakthrough in cancer treatment in recent years, but its efficacy is still limited by the immunosuppressive mechanisms within the tumor microenvironment (TME). The TME supports the differentiation and proliferation of mye...

Enhancing Immunotherapy Through PD-L1 Upregulation: The Promising Combination of Anti-PD-L1 Plus mTOR Inhibitors

Enhancing Immunotherapy Potential Through PD-L1 Upregulation—Combination of Anti-PD-L1 and mTOR Inhibitors Background Introduction In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly in the treatment of urothelial cancer (UC). PD-1/PD-L1 inhibitors restore T cell anti-tumor activity ...

Targeting SRSF10 Might Inhibit M2 Macrophage Polarization and Potentiate Anti-PD-1 Therapy in Hepatocellular Carcinoma

The Role of SRSF10 in Immunotherapy for Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) ranks sixth in global cancer incidence and third in mortality. Although surgical resection is the primary treatment for HCC, the high postoperative recurrence rate significantly impacts patient prognosis. In recent years, immunotherap...